Our study highlights a novel miR-365-HOXA9-HIF-1α regulatory axis underlying the enhanced glycolytic metabolism and tumor development in cSCC, which provides novel intervention targets for cSCC therapy. This evidence concerns the gene HOXA9 and neoplasm.